Shanghai, China, October 20, 2021 – Genor Biopharma (Stock code: 6998.HK) announced today that Mr. LIANG Qibin, the former President of CMAB Biopharma, will join Genor Biopharma as Chief Technology Officer. Dr. KAN Ziyi, the former CTO of Genor Biopharma, will leave the company in the near future to seek new opportunities.
As one of the first local innovative biotech enterprises, Genor Biopharma has its industry leading R&D center located in Shanghai focuses on CMC (Chemistry, Manufacturing, and Controls) development. This center is capable of developing comprehensive bioprocesses and formulations, and manufacturing preclinical and clinical materials with advanced analytical, quality control, and quality assurance systems for compliance.
Dr. GUO Feng, Executive Director of Genor Biopharma and CEO of the Group, said: “With Mr. LIANG Qibin joining the company, it will further strengthen the innovation ability of core technologies and achieve efficient innovation in technology, research and development, processes, management and other areas.”
Mr. Liang has around 30 years of experience in the operation and management in the CMC and production departments of internationally renowned biopharmaceutical companies and is an outstanding expert in biologics development, production and management. Mr. Liang has been responsible for the development and scale-up of biopharmaceutical process, technology transfer and the quality management during his time at Genentech Inc., Bayer Corporation and Progenics Pharmaceuticals, Inc. etc. in the United States of America (the “United States”). Apart from his experience in the United States, Mr. Liang has also led the establishment and operation of 3 Chinese biopharmaceutical companies, including Wuxi AppTec, MabPlex International and CMAB Biopharma Inc. During his time serving these 3 Chinese biopharmaceutical companies, he has acquired extensive experience in, among others, the establishment of hardware and software, the establishment of biopharmaceutical process, and the establishment of quality and GMP system, team building and personnel management.
In recent years, Genor Biopharma has continuously recruited senior management talent:
- HAN Shuhua joined as Chief Scientist of the Group in January 2021. With over 25 years’ experience in drug discovery and academic research in the fields of immunology, cancer immunotherapy, oncology, autoimmune diseases and inflammation, Dr. Han will lead the company’s in-house research and discovery efforts and accelerate its footprint toward building a world-class innovation engine.
- Mark F. Kubik joined the company as Chief Business Officer in August 2021. Mr. Kubik has over 25 years of experience in business development, alliance and portfolio management, and drug discovery and development. He will support the acceleration of the business development of Genor Biopharma globally and in China.
Genor Biopharma is maximizing its advantages as a world-class China-based innovative biopharmaceutical company through its integrated biopharmaceutical platform, and actively addressing unmet medical needs of patients in China and gradually for patients globally through R&D and pipeline expansion.
